Parker Waichman LLP Files Suit On Behalf of Alleged Fosamax Femur Fracture VictimsMar 2, 2012 | Parker Waichman LLP
Parker Waichman LLP has filed lawsuits on behalf of two women who say they suffered femur fractures after using the drug Fosamax for several years. Fosamax is a member of a class of drugs known as bisphosphonates which treat bone disorders like osteoporosis.
Both lawsuits were filed in the Superior Court of New Jersey. Fosamax lawsuits have been designated a mass tort there. Both suits were filed Merck Sharp & Dohme Corp. f/k/a Merck & Co., Watson Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.
Plaintiff Irene Zarra, a resident of Pennsylvania, took Fosamax consistently from September 5, 2004 to February 2010, when she suffered a femur fracture. In the second lawsuit, plaintiff Lucille Handle of Connecticut consistently took the drug between January 21, 2006 and February 25, 2010. On February 25, 2010, Ms. Handle suffered a right femur fracture. On November 23, 2010, she sustained a fracture to her left femur.
Both lawsuits allege that as a result of their long-term Fosamax use, Ms. Zarra and Ms. Handle suffered severe mental and physical pain and suffering, and have and will continue to sustain permanent injuries and emotional distress, along with economic losses resulting from medical expenses and living-related expenses related to their new lifestyle.
The women are seeking compensatory, punitive and treble damages, as well as ascertainable economic losses, reimbursement of the cost of Fosamax, reimbursement for all past, present and future health and medical costs related to Fosamax, and derivative damages on behalf of the plaintiffs.